FAGRB Stock Overview
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 3/6 |
Financial Health | 4/6 |
Dividends | 2/6 |
Fagron NV Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €16.66 |
52 Week High | €17.43 |
52 Week Low | €14.72 |
Beta | 0.29 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | 10.48% |
3 Year Change | -12.20% |
5 Year Change | 1.55% |
Change since IPO | -52.82% |
Recent News & Updates
Recent updates
Shareholder Returns
FAGRB | GB Healthcare | GB Market | |
---|---|---|---|
7D | 0% | -1.9% | 2.1% |
1Y | 10.5% | -22.2% | 3.8% |
Return vs Industry: FAGRB exceeded the UK Healthcare industry which returned -13.3% over the past year.
Return vs Market: FAGRB exceeded the UK Market which returned -5.4% over the past year.
Price Volatility
FAGRB volatility | |
---|---|
FAGRB Average Weekly Movement | n/a |
Healthcare Industry Average Movement | 7.6% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.2% |
10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: FAGRB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine FAGRB's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1990 | 3,035 | Rafael Padilla | https://www.fagron.com |
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding.
Fagron NV Fundamentals Summary
FAGRB fundamental statistics | |
---|---|
Market cap | €1.30b |
Earnings (TTM) | €70.55m |
Revenue (TTM) | €762.99m |
18.5x
P/E Ratio1.7x
P/S RatioIs FAGRB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FAGRB income statement (TTM) | |
---|---|
Revenue | €762.99m |
Cost of Revenue | €430.38m |
Gross Profit | €332.61m |
Other Expenses | €262.07m |
Earnings | €70.55m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 01, 2024
Earnings per share (EPS) | 0.97 |
Gross Margin | 43.59% |
Net Profit Margin | 9.25% |
Debt/Equity Ratio | 69.6% |
How did FAGRB perform over the long term?
See historical performance and comparison